Efficacy and Safety of 2 Fixed Doses of Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced HIV-Positive Individuals
In heavily treatment-experienced patients with HIV (PWH) at a more advanced baseline disease severity, clinically significant response rates at week 24 were achieved with ibalizumab plus OBR. Ibalizumab's unique mechanism of action and lack of cross-resistance to other antiretroviral agents make it an important component of combination treatment regimens for PWH with limited treatment options.
Authors
- Kaitlin Anstett (ORCID: https://orcid.org/0000-0002-6051-5503)
- Edwin DeJesus
- William James Towner (ORCID: https://orcid.org/0000-0001-5645-2979)
- R Brandon Cash
- Joseph Gathe
Institutions
- Kaiser Permanente (US)
- KCI (United States) (US)
- Orlando Immunology Center (US)
- Theratechnologies (Canada) (CA)
Publication Details
- Journal
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1097/qai.0000000000003524
- Citations
- 3
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.88